In turn, targeting of SSX2 is being explored using multi tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes in patients with breast cancer (TACTIC study, NCT03093350), pancreatic cancer (TACTOPS study, NCT03192462) and lymphoma (NCT01333046).209. The gene discussed is SSX2; the disease is breast carcinoma.